Human sCD23 ELISA kit

Name: Human sCD23 ELISA kit
SKU: DEIA-BJ469
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, cell culture supernatants, body fluid and tissue homogenate

Species Reactivity

Human

Detection Method

Sandwich ELISA

Intended Use

Human sCD23 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of the sCD23. This ELISA kit is for research use only, not for therapeutic or diagnostic applications.

Contents of Kit

1. MICROTITER PLATE: 96 wells
2. ENZYME CONJUGATE: 6.0 mL or 10 ml
3. STANDARD A-F: 1 vial each
4. SUBSTRATE A: 6 mL
5. SUBSTRATE B: 6 mL
6. STOP SOLUTION: 6 mL
7. WASH SOLUTION (100 x): 10 mL
8. BALANCE SOLUTION: 3 mL

Storage

All components of this kit are stable at 2-8°C until the kit's expiration date.

Detection Range

0-500 U/ml

Sensitivity

1.0 U/ml

Citations

Have you cited DEIA-BJ469 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy

HUMAN PATHOLOGY

Authors: Siddique, Ayesha S.; Corney, David C.; Mangray, Shamlal; Lombardo, Kara A.; Chen, Sonja; Marwaha, Alexander S.; Resnick, Murray B.; Herzlinger, Michael; Matoso, Andres

Abstract

Some patients with eosinophilic esophagitis (EoE) do not respond to therapy. The clinicopathologic characteristics and gene expression profile at time of presentation could help predict response to therapy. Refractory EoE was defined as persistence of symptoms and biopsies with histologic features of EoE after 6 months of therapy with proton pump inhibitors and topical corticosteroids. Initial biopsies from refractory EoE patients (n = 21), responder to therapy (n = 8), patients who relapsed (n = 6), and reflux controls (n = 24) were studied. RNA was isolated from a subset of cases, and gene expression analysis of 285 genes involved in inflammation was performed using NanoString technology. There was no difference in the presenting symptoms among groups. The number of eosinophils/high-power field among nonresponders was higher (66 +/- 15) than responders (39 +/- 8; P < .0001) and similar to patients who relapsed (62 +/- 11). Six genes were expressed by at least 4-fold compared with reflux at a false discovery rate < 0.05, including overexpression of ALOXI 5, CCL26, FCER2, RTNLB, and RNASE2, and underexpression of DSG1. EoE patients refractory to therapy or who relapsed showed a trend toward higher ALOXI 5 expression compared with patients with good response to therapy (364.4- and 425-fold change, P =.097 and P = .07). RTNLB was significantly overexpressed in patients who were refractory to therapy versus those who responded favorably (10-fold versus 3-fold; P < .01). In conclusion, the number of eosinophils/high-power field in the initial biopsy inversely correlates with therapy response. Overexpression of RTNLB in refractory-to-therapy patients and overexpression of ALOXI.5 and CCL26 suggest that they are critical in the EoE pathogenesis. (C) 2017 Elsevier Inc. All rights reserved.

Asthma-related SNP in FCER2 is associated with increased expression of IL-4R on human B cells

INTERNATIONAL JOURNAL OF IMMUNOGENETICS

Authors: Chan, M. A.; Gigliotti, N. M.; Meng, J.; Rosenwasser, L. J.

Abstract

A SNP (rs2228137) (R62W) in FCER2 has been linked with severe exacerbations in asthmatics. Transfectants expressing the SNP exhibited increased IL-4Ra expression after stimulation through CD23 compared with wild-type. Our data suggest that the SNP may favour increased IgE production through increased responsiveness to IL-4 in patients possessing this genotype.